Ranzani O, Alari A, Olmos S, Mila C, Rico A, Ballester J, Basagana X, Chaccour C, Dadvand P, Duarte-Salles T, Foraster M, Nieuwenhuijsen M, Sunyer J, Valentin A, Kogevinas M, Lazcano U, Avellaneda-Gomez C, Vivanco R, Tonne C. Long-term exposure to air pollution and severe COVID-19 in Catalonia: a population-based cohort study. Nat Commun. 2023 May 24;14(1):2916. doi: 10.1038/s41467-023-38469-7
Oser TK, Minnehan KA, Wong G, Parascando J, McGinley (Miller) E, Radico J, Oser SM. Using social media to broaden understanding of the barriers and facilitators to exercise in adults with type 1 diabetes. J Diabetes Sci Technol. 2019 May;13(3):457-65. doi: 10.1177/1932296819835787
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.